{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-23-000020","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.350407+00:00","generated_at":"2026-06-19T09:17:07.821807+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Skye Bioscience appoints Dr. Deborah Charych to Board of Directors; director Rai resigns","bullets":["Bobby Rai resigned from Board and Nominating Committee effective Feb 14, 2023; not due to any disagreement.","Dr. Deborah Charych elected to fill the vacancy; will receive $40,000 annual cash compensation.","Charych granted options to purchase 250,000 shares, vesting monthly over one year.","Charych co-founded RayzeBio, led R&D strategy raising $418M; previously led Nektar deal with Bristol Myers for $1.8B.","Her background includes GPCR and cannabinoid receptor biology, relevant to Skye's glaucoma drug development."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-23-000020","json":"https://secwatch.observer/filing/0001516551-23-000020.json","markdown":"https://secwatch.observer/filing/0001516551-23-000020.md","text":"https://secwatch.observer/filing/0001516551-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/0001516551-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/skye-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:17:07.821807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cad3ea2097","claim":"Bobby Rai resigned as Director at Skye Bioscience, Inc..","evidence_excerpt":"On February 14, 2023, Bobby Rai resigned as a member of the Board of Directors (the \"Board\") of Skye Bioscience, Inc. (the \"Company\") and the Nominating and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/0001516551-23-000020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d4a5c2ee6d","claim":"Deborah Charych was elected as Director at Skye Bioscience, Inc..","evidence_excerpt":"On February 14, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Dr. Deborah Charych, Ph.D. to fill the vacancy created by Mr. Rai's resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/0001516551-23-000020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}